<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="editorial" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">KmqKwkptKgmNDgg6ZNXg75C</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2025000600205</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20250518</article-id>
      <article-id pub-id-type="other">00205</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Minieditorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Explorando o Escore Progn&#243;stico de N&#225;poles: Uma Chave para Prever o In&#237;cio da Fibrila&#231;&#227;o Atrial em Casos de IAMCCST</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-6723-5758</contrib-id>
          <name>
            <surname>Dourado</surname>
            <given-names>Paulo Magno Martins</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <aff id="aff1">
          <label>1</label>
          <institution content-type="orgname">Faculdade de Medicina da Universidade de S&#227;o Paulo</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
        <aff id="aff2">
          <label>2</label>
          <institution content-type="orgname">Cl&#237;nica Pr&#243;-Cora&#231;&#227;o</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Cl&#237;nica Pr&#243;-Cora&#231;&#227;o, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><label>Correspond&#234;ncia:</label><bold>Paulo Magno Martins Dourado</bold> &#8226; Faculdade de Medicina da Universidade de S&#227;o Paulo &#8211; Av. Dr. Eneas Carvalho de Aguiar, 44. CEP <postal-code>05403-000</postal-code>, Pinheiros, S&#227;o Paulo, SP &#8211; Brasil E-mail: <email>pmdourado@terra.com.br</email></corresp>
      </author-notes>
      <pub-date publication-format="electronic" date-type="pub">
        <day>04</day>
        <month>08</month>
        <year>2025</year>
      </pub-date>
      <pub-date publication-format="electronic" date-type="collection">
        <year>2025</year>
      </pub-date>
      <volume>122</volume>
      <issue>6</issue>
      <elocation-id>e20250218</elocation-id>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>03</month>
          <year>2025</year>
        </date>
        <date date-type="rev-recd">
          <day>14</day>
          <month>04</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>04</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xml:lang="en" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Fibrila&#231;&#227;o atrial</kwd>
        <kwd>Infarto do Mioc&#225;rdio com Supradesn&#237;vel do Segmento ST</kwd>
        <kwd>Progn&#243;stico</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="12"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>No cen&#225;rio em constante evolu&#231;&#227;o do tratamento card&#237;aco, o Escore Progn&#243;stico de N&#225;poles (Naples Prognostic Score &#8211; (NPS)) surgiu como uma ferramenta promissora para prever o in&#237;cio da fibrila&#231;&#227;o atrial (FA) em pacientes com infarto agudo do mioc&#225;rdio com supradesnivelamento do segmento ST (IAMCSST).<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Este sistema de pontua&#231;&#227;o inovador oferece insights sobre os desfechos dos pacientes e capacita os profissionais de sa&#250;de a tomar decis&#245;es informadas em tempo real. Compreender e utilizar este escore pode aprimorar o manejo do paciente e aumentar as taxas de sobrevida. Vamos explorar como o NPS transforma a abordagem para a predi&#231;&#227;o de IAMCSST e FA.</p>
    <p>A FA ap&#243;s IAMCSST &#233; uma preocupa&#231;&#227;o crescente na &#225;rea da medicina cardiovascular.&#178; O cen&#225;rio p&#243;s-IM apresenta in&#250;meros desafios, com a FA amplificando significativamente o risco de desfechos adversos para os pacientes. Um estudo recente que destaca o NPS traz novas esperan&#231;as na busca por prever e tratar complica&#231;&#245;es de forma eficaz ap&#243;s o infarto do mioc&#225;rdio.&#179; Reconhecer o potencial para a detec&#231;&#227;o precoce de FA de in&#237;cio recente (FANO) &#8212; uma condi&#231;&#227;o associada ao aumento da morbidade e mortalidade &#8212; melhora a qualidade do atendimento prestado a pacientes com IAMCSST submetidos &#224; interven&#231;&#227;o coron&#225;ria percut&#226;nea prim&#225;ria.<sup><xref ref-type="bibr" rid="B4">4</xref></sup></p>
    <p>O NPS &#233; uma ferramenta abrangente que integra v&#225;rios biomarcadores indicativos de um estado pr&#243;-inflamat&#243;rio, sendo os principais componentes a rela&#231;&#227;o neutr&#243;filo-linf&#243;cito e a rela&#231;&#227;o linf&#243;cito-mon&#243;cito. Esses biomarcadores s&#227;o cruciais para delinear o estado inflamat&#243;rio de um paciente e compreender seu estado nutricional &#8212; elementos que se tornaram cada vez mais vitais na previs&#227;o de desfechos cardiovasculares. A integra&#231;&#227;o desses par&#226;metros permite que os m&#233;dicos avaliem o risco de forma mais eficaz, adaptando-o ao perfil fisiol&#243;gico &#250;nico de cada paciente.<sup><xref ref-type="bibr" rid="B5">5</xref></sup></p>
    <p>A import&#226;ncia da FA ap&#243;s IAMCSST n&#227;o pode ser superestimada. Apesar dos avan&#231;os em t&#233;cnicas intervencionistas e estrat&#233;gias de tratamento agudo, o IAMCSST continua sendo uma das principais causas de morbidade e mortalidade em todo o mundo. O advento da FA p&#243;s-IAMCSST complica o manejo, levando a desafios persistentes, como altera&#231;&#245;es hemodin&#226;micas, disfun&#231;&#227;o diast&#243;lica e aumento do risco de eventos tromboemb&#243;licos, incluindo acidente vascular cerebral. Ao elucidar o poder preditivo do NPS, os pesquisadores est&#227;o abrindo caminho para a identifica&#231;&#227;o de indiv&#237;duos de alto risco que podem se beneficiar de um monitoramento mais intensivo e terapias direcionadas.<sup><xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup></p>
    <p>Um dos aspectos mais importantes do NPS &#233; sua capacidade de sinalizar pacientes com risco aumentado de FANO durante o per&#237;odo cr&#237;tico ap&#243;s o IAMCSST. A identifica&#231;&#227;o precoce desses indiv&#237;duos permite que os m&#233;dicos implementem medidas proativas, seja por meio de monitoramento mais rigoroso ou do in&#237;cio de estrat&#233;gias preventivas, para mitigar a incid&#234;ncia de complica&#231;&#245;es perigosas. As implica&#231;&#245;es dos resultados do estudo s&#227;o profundas, pois motivam uma mudan&#231;a em dire&#231;&#227;o &#224; medicina personalizada, onde as interven&#231;&#245;es podem ser adaptadas de acordo com o perfil de risco de cada indiv&#237;duo.<sup><xref ref-type="bibr" rid="B1">1</xref></sup></p>
    <p>Al&#233;m disso, a metodologia robusta empregada na valida&#231;&#227;o do NPS &#233; louv&#225;vel. Ao se basear em uma grande coorte, o estudo atinge poder estat&#237;stico significativo, aumentando a confiabilidade de suas conclus&#245;es. A distin&#231;&#227;o clara entre pacientes que desenvolvem FANO e aqueles que mant&#234;m ritmo sinusal acrescenta ainda mais clareza &#224; utilidade do NPS em ambientes cl&#237;nicos.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Esse n&#237;vel de conhecimento auxilia nos protocolos de tratamento atuais. Abre caminhos para pesquisas futuras, particularmente no que diz respeito &#224; incorpora&#231;&#227;o de marcadores inflamat&#243;rios e nutricionais em diversas popula&#231;&#245;es de pacientes, levando, em &#250;ltima an&#225;lise, a aplica&#231;&#245;es cl&#237;nicas mais amplas.</p>
    <p>Em uma era declaradamente focada em melhorar os resultados dos pacientes, o potencial do NPS para revolucionar a forma como os m&#233;dicos abordam os casos de IAMCSST &#233; significativo. Incorporar o NPS &#224; pr&#225;tica cl&#237;nica de rotina pode gerar uma mudan&#231;a de paradigma nas abordagens de estratifica&#231;&#227;o de risco e no manejo terap&#234;utico dos pacientes, potencialmente levando a melhores resultados em v&#225;rias m&#233;tricas de sucesso.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> No entanto, &#224; medida que adotamos esses avan&#231;os, a comunidade m&#233;dica deve agir com cautela, garantindo que ferramentas progn&#243;sticas como o NPS sejam utilizadas criteriosamente. A natureza multifatorial da FA deve permanecer na vanguarda da considera&#231;&#227;o cl&#237;nica, reconhecendo que, embora os biomarcadores forne&#231;am insights valiosos, eles n&#227;o levam em conta todos os elementos que influenciam o bem-estar do paciente.</p>
    <p>A rela&#231;&#227;o entre inflama&#231;&#227;o, nutri&#231;&#227;o e sa&#250;de cardiovascular &#233; cada vez mais reconhecida, mas merece maior explora&#231;&#227;o.<sup><xref ref-type="bibr" rid="B8">8</xref>&#8211;<xref ref-type="bibr" rid="B10">10</xref></sup> O NPS serve como uma base promissora para iniciar esse discurso.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> Estudos futuros podem expandir os achados iniciais, integrando uma gama mais ampla de biomarcadores e explorando suas intera&#231;&#245;es com comorbidades que frequentemente acompanham o IAMCSST, como diabetes mellitus, insufici&#234;ncia renal e doen&#231;a pulmonar obstrutiva cr&#244;nica.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> Essa compreens&#227;o hol&#237;stica pode impulsionar inova&#231;&#245;es em estrat&#233;gias terap&#234;uticas e permitir que os m&#233;dicos abordem o estado de sa&#250;de abrangente de cada paciente de forma mais eficaz.</p>
    <p>Em conclus&#227;o, o NPS avan&#231;a significativamente nossa compreens&#227;o dos fatores preditivos associados &#224; FANO no contexto do IAMCSST.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> O NPS fornece uma estrutura inovadora para aprimorar o atendimento ao paciente, entrela&#231;ando os conceitos de inflama&#231;&#227;o e estado nutricional.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B12">12</xref></sup> As implica&#231;&#245;es dessas descobertas v&#227;o al&#233;m do mero interesse acad&#234;mico; elas t&#234;m o potencial de revelar novos insights sobre o manejo de uma das complica&#231;&#245;es mais complexas e desafiadoras da medicina cardiovascular. Embora a perspectiva otimista em torno do NPS seja justificada, pesquisas cont&#237;nuas devem ser conduzidas com a m&#225;xima cautela e responsabilidade para garantir que os avan&#231;os nessa &#225;rea se traduzam efetivamente em melhores pr&#225;ticas cl&#237;nicas e desfechos para os pacientes.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other" id="fn1">
        <label>Minieditorial referente ao artigo:</label>
        <p>O Escore Progn&#243;stico de N&#225;poles Prev&#234; Fibrila&#231;&#227;o Atrial de In&#237;cio Recente em Pacientes com Infarto do Mioc&#225;rdio com Supradesnivelamento do Segmento ST Submetidos &#224; Angioplastia Prim&#225;ria</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oksen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Arslan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gecit</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Tekin</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Oktay</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Naples Prognostic Score Predicts New-Onset Atrial Fibrillation in Patients with ST-Elevated Myocardial Infarction Undergoing Primary Angioplasty</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2025</year>
          <volume>122</volume>
          <issue>6</issue>
          <elocation-id>e20240671</elocation-id>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20240671i">https://doi.org/10.36660/abc.20240671i</ext-link>
          </comment>
        </element-citation>
        <mixed-citation>1 Oksen D, Arslan S, Gecit MH, Tekin EE, Oktay V, et al. Naples Prognostic Score Predicts New-Onset Atrial Fibrillation in Patients with ST-Elevated Myocardial Infarction Undergoing Primary Angioplasty. Arq Bras Cardiol. 2025; 122(6):e20240671. DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20240671i">https://doi.org/10.36660/abc.20240671i</ext-link>.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byrne</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Rossello</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Coughlan</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Barbato</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chieffo</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>2023 ESC Guidelines for the Management of Acute Coronary Syndromes</article-title>
          <source>Eur Heart J Acute Cardiovasc Care</source>
          <year>2024</year>
          <volume>13</volume>
          <issue>1</issue>
          <fpage>55</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="doi">10.1093/ehjacc/zuad107</pub-id>
        </element-citation>
        <mixed-citation>2 Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. Eur Heart J Acute Cardiovasc Care. 2024;13(1):55-161. doi: 10.1093/ehjacc/zuad107.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erdogan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Genc</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ozkan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Goksu</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Ibisoglu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bilen</surname>
              <given-names>MN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of Naples Prognostic Score at Admission on in-Hospital and Follow-Up Outcomes Among Patients with ST-Segment Elevation Myocardial Infarction</article-title>
          <source>Angiology</source>
          <year>2023</year>
          <volume>74</volume>
          <issue>10</issue>
          <fpage>970</fpage>
          <lpage>980</lpage>
          <pub-id pub-id-type="doi">10.1177/00033197231151559</pub-id>
        </element-citation>
        <mixed-citation>3 Erdogan A, Genc O, Ozkan E, Goksu MM, Ibisoglu E, Bilen MN, et al. Impact of Naples Prognostic Score at Admission on in-Hospital and Follow-Up Outcomes Among Patients with ST-Segment Elevation Myocardial Infarction. Angiology. 2023;74(10):970-80. doi: 10.1177/00033197231151559.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arslan</surname>
              <given-names>&#350;</given-names>
            </name>
            <name>
              <surname>Bat&#305;t</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>K&#305;l&#305;&#231;arslan</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Do&#287;an</surname>
              <given-names>&#214;</given-names>
            </name>
            <name>
              <surname>Yumuk</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Arslan</surname>
              <given-names>&#350;</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Incidence of Atrial Fibrillation and its Effects on Long-Term Follow-Up Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction</article-title>
          <source>Anatol J Cardiol</source>
          <year>2021</year>
          <volume>25</volume>
          <issue>9</issue>
          <fpage>609</fpage>
          <lpage>616</lpage>
          <pub-id pub-id-type="doi">10.5152/AnatolJCardiol.2021.26020</pub-id>
        </element-citation>
        <mixed-citation>4 Arslan &#350;, Bat&#305;t S, K&#305;l&#305;&#231;arslan O, Do&#287;an &#214;, Yumuk MT, Arslan &#350;, et al. Incidence of Atrial Fibrillation and its Effects on Long-Term Follow-Up Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Anatol J Cardiol. 2021;25(9):609-16. doi: 10.5152/AnatolJCardiol.2021.26020.</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galizia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lieto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Auricchio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cardella</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mabilia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Podzemny</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-Term Outcome in Patients Undergoing Surgery for Colorectal Cancer</article-title>
          <source>Dis Colon Rectum</source>
          <year>2017</year>
          <volume>60</volume>
          <issue>12</issue>
          <fpage>1273</fpage>
          <lpage>1284</lpage>
          <pub-id pub-id-type="doi">10.1097/DCR.0000000000000961</pub-id>
        </element-citation>
        <mixed-citation>5 Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Podzemny V, et al. Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-Term Outcome in Patients Undergoing Surgery for Colorectal Cancer. Dis Colon Rectum. 2017;60(12):1273-84. doi: 10.1097/DCR.0000000000000961.</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazzone</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scalese</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Paradossi</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Del Turco</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Botto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>De Caterina</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Development and Validation of a Risk Stratification Score for New-Onset Atrial Fibrillation in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention</article-title>
          <source>Int J Clin Pract</source>
          <year>2018</year>
          <volume>72</volume>
          <issue>4</issue>
          <elocation-id>e13087</elocation-id>
          <pub-id pub-id-type="doi">10.1111/ijcp.13087</pub-id>
        </element-citation>
        <mixed-citation>6 Mazzone A, Scalese M, Paradossi U, Del Turco S, Botto N, De Caterina A, et al. Development and Validation of a Risk Stratification Score for New-Onset Atrial Fibrillation in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention. Int J Clin Pract. 2018;72(4):e13087. doi: 10.1111/ijcp.13087.</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rene</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>G&#233;n&#233;reux</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ezekowitz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kirtane</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mehran</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of Atrial Fibrillation in Patients with ST-Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention (from the HORIZONS-AMI [Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction] Trial)</article-title>
          <source>Am J Cardiol</source>
          <year>2014</year>
          <volume>113</volume>
          <issue>2</issue>
          <fpage>236</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjcard.2013.09.016</pub-id>
        </element-citation>
        <mixed-citation>7 Rene AG, G&#233;n&#233;reux P, Ezekowitz M, Kirtane AJ, Xu K, Mehran R, et al. Impact of Atrial Fibrillation in Patients with ST-Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention (from the HORIZONS-AMI [Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction] Trial). Am J Cardiol. 2014;113(2):236-42. doi: 10.1016/j.amjcard.2013.09.016.</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mourouzis</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oikonomou</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Siasos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tsalamadris</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vogiatzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Antonopoulos</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pro-Inflammatory Cytokines in Acute Coronary Syndromes</article-title>
          <source>Curr Pharm Des</source>
          <year>2020</year>
          <volume>26</volume>
          <issue>36</issue>
          <fpage>4624</fpage>
          <lpage>4647</lpage>
          <pub-id pub-id-type="doi">10.2174/1381612826666200413082353</pub-id>
        </element-citation>
        <mixed-citation>8 Mourouzis K, Oikonomou E, Siasos G, Tsalamadris S, Vogiatzi G, Antonopoulos A, et al. Pro-Inflammatory Cytokines in Acute Coronary Syndromes. Curr Pharm Des. 2020;26(36):4624-47. doi: 10.2174/1381612826666200413082353.</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozaydin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peker</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Erdogan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Akcay</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yucel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Icli</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oxidative Status, Inflammation, and Postoperative Atrial Fibrillation with Metoprolol vs Carvedilol or Carvedilol Plus N-Acetyl Cysteine Treatment</article-title>
          <source>Clin Cardiol</source>
          <year>2014</year>
          <volume>37</volume>
          <issue>5</issue>
          <fpage>300</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="doi">10.1002/clc.22249</pub-id>
        </element-citation>
        <mixed-citation>9 Ozaydin M, Peker O, Erdogan D, Akcay S, Yucel H, Icli A, et al. Oxidative Status, Inflammation, and Postoperative Atrial Fibrillation with Metoprolol vs Carvedilol or Carvedilol Plus N-Acetyl Cysteine Treatment. Clin Cardiol. 2014;37(5):300-6. doi: 10.1002/clc.22249.</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bas</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Aksoy</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Icli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Varol</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dogan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Erdogan</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Association of Plasma Oxidative Status and Inflammation with the Development of Atrial Fibrillation in Patients Presenting with ST Elevation Myocardial Infarction</article-title>
          <source>Scand J Clin Lab Invest</source>
          <year>2017</year>
          <volume>77</volume>
          <issue>2</issue>
          <fpage>77</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1080/00365513.2016.1244857</pub-id>
        </element-citation>
        <mixed-citation>10 Bas HA, Aksoy F, Icli A, Varol E, Dogan A, Erdogan D, et al. The Association of Plasma Oxidative Status and Inflammation with the Development of Atrial Fibrillation in Patients Presenting with ST Elevation Myocardial Infarction. Scand J Clin Lab Invest. 2017;77(2):77-82. doi: 10.1080/00365513.2016.1244857.</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karam</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Chavez-Moreno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Akar</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Akar</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
          <article-title>Oxidative Stress and Inflammation as Central Mediators of Atrial Fibrillation in Obesity and Diabetes</article-title>
          <source>Cardiovasc Diabetol</source>
          <year>2017</year>
          <volume>16</volume>
          <issue>1</issue>
          <fpage>120</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="doi">10.1186/s12933-017-0604-9</pub-id>
        </element-citation>
        <mixed-citation>11 Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative Stress and Inflammation as Central Mediators of Atrial Fibrillation in Obesity and Diabetes. Cardiovasc Diabetol. 2017;16(1):120. doi: 10.1186/s12933-017-0604-9.</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Birdal</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Pay</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aksakal</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yumurta&#351;</surname>
              <given-names>A&#199;</given-names>
            </name>
            <name>
              <surname>&#199;inier</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Y&#252;cel</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Naples Prognostic Score and Prediction of Left Ventricular Ejection Fraction in STEMI Patients</article-title>
          <source>Angiology</source>
          <year>2024</year>
          <volume>75</volume>
          <issue>1</issue>
          <fpage>36</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1177/00033197231161903</pub-id>
        </element-citation>
        <mixed-citation>12 Birdal O, Pay L, Aksakal E, Yumurta&#351; A&#199;, &#199;inier G, Y&#252;cel E, et al. Naples Prognostic Score and Prediction of Left Ventricular Ejection Fraction in STEMI Patients. Angiology. 2024;75(1):36-43. doi: 10.1177/00033197231161903.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="S1" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20250518i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Exploring the Naples Prognostic Score: A Key to Predicting New-Onset Atrial Fibrillation in STEMI Cases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-6723-5758</contrib-id>
          <name>
            <surname>Dourado</surname>
            <given-names>Paulo Magno Martins</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <aff id="aff3">
          <label>1</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
        <aff id="aff4">
          <label>2</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Cl&#237;nica Pr&#243;-Cora&#231;&#227;o, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><label>Mailing Address:</label><bold>Paulo Magno Martins Dourado</bold> &#8226; Faculdade de Medicina da Universidade de S&#227;o Paulo &#8211; Av. Dr. Eneas Carvalho de Aguiar, 44. Postal Code <postal-code>05403-000</postal-code>, Pinheiros, S&#227;o Paulo, SP &#8211; Brazil E-mail: <email>pmdourado@terra.com.br</email></corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Atrial Fibrillation</kwd>
        <kwd>ST Elevation Myocardial Infarction</kwd>
        <kwd>Prognosis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>In the ever-evolving landscape of cardiac care, the Naples Prognostic Score (NPS) has emerged as a promising tool for predicting the onset of atrial fibrillation (AF) in patients experiencing ST-segment elevation myocardial infarction (STEMI).<sup><xref ref-type="bibr" rid="B1">1</xref></sup> This innovative scoring system offers insights into patient outcomes and empowers healthcare providers to make real-time, informed decisions. Understanding and utilizing this score can enhance patient management and improve survival rates. Let us explore how the NPS transforms the approach to STEMI and AF prediction.</p>
      <p>AF following STEMI is a rising concern in the field of cardiovascular medicine.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> The post-MI landscape presents myriad challenges, with AF significantly amplifying the risk of adverse outcomes for patients. A recent study highlighting the NPS brings new hope in the quest to predict and manage complications effectively after myocardial infarction.<sup><xref ref-type="bibr" rid="B3">3</xref></sup> Recognizing the potential for early detection of new-onset AF (NOAF) &#8212;a condition associated with increased morbidity and mortality&#8212;enhances the quality of care delivered to STEMI patients undergoing primary percutaneous coronary intervention.<sup><xref ref-type="bibr" rid="B4">4</xref></sup></p>
      <p>The NPS is a comprehensive tool that integrates various biomarkers indicative of a pro-inflammatory state, with key components being the neutrophil-to-lymphocyte ratio and the lymphocyte-to-monocyte ratio. These biomarkers are crucial for delineating a patient's inflammatory status and understanding their nutritional status&#8212;elements that have become increasingly vital in predicting cardiovascular outcomes. Integrating these parameters allows clinicians to assess risk more effectively, tailored to each patient's unique physiological profile.<sup><xref ref-type="bibr" rid="B5">5</xref></sup></p>
      <p>The significance of AF following STEMI cannot be overstated. Despite advancements in interventional techniques and acute care strategies, STEMI remains one of the leading causes of morbidity and mortality worldwide. The advent of AF post-STEMI complicates management, leading to persistent challenges such as altered hemodynamics, diastolic dysfunction, and an increased risk of thromboembolic events, including stroke. By illuminating the predictive power of the NPS, researchers are paving the way for identifying high-risk individuals who may benefit from more intensive monitoring and targeted therapies.<sup><xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref></sup></p>
      <p>One of the most potent aspects of the NPS is its capacity to flag patients at an increased risk for NOAF during the critical period following STEMI. Early identification of these individuals enables clinicians to implement proactive measures, be it through closer monitoring or the initiation of preventive strategies, to mitigate the incidence of dangerous complications. The implications of the study's findings are profound, as they motivate a shift toward personalized medicine where interventions can be tailored according to an individual's risk profile.<sup><xref ref-type="bibr" rid="B1">1</xref></sup></p>
      <p>Moreover, the robust methodology employed in validating the NPS is commendable. By drawing upon a large cohort, the study attains significant statistical power, enhancing the reliability of its conclusions. The clear distinction between patients who develop NOAF and those who maintain sinus rhythm adds further clarity to the utility of the NPS in clinical settings.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> This level of insight assists in current treatment protocols. It opens avenues for future research, particularly regarding incorporating inflammatory and nutritional markers across diverse patient populations, ultimately leading to broader clinical applications.</p>
      <p>In an era avowedly focused on enhancing patient outcomes, the potential of the NPS to revolutionize how clinicians approach STEMI cases is significant. Incorporating the NPS into routine clinical practice could engender a paradigm shift in risk stratification approaches and the therapeutic management of patients, potentially leading to better outcomes across various success metrics.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> However, as we embrace these advancements, the medical community must tread carefully, ensuring that prognostic tools like the NPS are utilized judiciously. The multifactorial nature of AF must remain at the forefront of clinical consideration, acknowledging that while biomarkers provide valuable insights, they do not account for every element influencing patient well-being.</p>
      <p>The relationship between inflammation, nutrition, and cardiovascular health is increasingly acknowledged but warrants further exploration.<sup><xref ref-type="bibr" rid="B8">8</xref>&#8211;<xref ref-type="bibr" rid="B10">10</xref></sup> The NPS serves as a promising foundation for beginning that discourse.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> Future studies could expand upon the initial findings by integrating a wider array of biomarkers and exploring their interactions with comorbidities often accompanying STEMI, such as diabetes mellitus, renal impairment, and chronic obstructive pulmonary disease.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> This holistic understanding may drive innovations in therapeutic strategies and enable clinicians to address each patient's comprehensive health status more effectively.</p>
      <p>In conclusion, the NPS significantly advances our understanding of predictive factors associated with NOAF within the STEMI context.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup> The NPS provides a groundbreaking framework for enhancing patient care by intertwining inflammation and nutritional status concepts.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B12">12</xref></sup> The implications of these findings extend beyond mere academic interest; they hold the potential to unlock new insights into managing one of cardiovascular medicine's most complex and challenging complications. While the optimistic outlook surrounding the NPS is warranted, continued inquiry must be conducted with the utmost caution and responsibility to ensure that developments in this area translate effectively into improved clinical practice and patient outcomes.</p>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other" id="fn2">
          <label>Short Editorial related to the article:</label>
          <p>Naples Prognostic Score Predicts New-Onset Atrial Fibrillation in Patients with ST-Elevated Myocardial Infarction Undergoing Primary Angioplasty</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
